Australia Markets open in 2 hrs 10 mins

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1990+0.0090 (+4.74%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1900
Bid0.1906 x 40700
Ask0.1999 x 1200
Day's range0.1900 - 0.2000
52-week range0.1900 - 2.0900
Avg. volume1,590,441
Market cap7.514M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)-2.9320
Earnings date29 Mar 2023 - 03 Apr 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Jan 2023
1y target est16.00
  • GlobeNewswire

    Catalyst Biosciences Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)

  • GlobeNewswire

    Catalyst Biosciences Completes First Steps in Reverse Merger Plan

    Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21

  • Simply Wall St.

    Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

    Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...